Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct acting anti-viral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19”.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit www.rhizen.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005815/en/
Contact information
Samyukta Bhagwati
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals S.A.
Telephone: +41 32 580 0113
Email: corpcomm@rhizen.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
World Leaders and Industry Icons Unite Under BRIDGE Alliance to Empower the Future of Media, Entertainment and Content12.11.2025 15:11:00 EET | Press release
A new international alliance of policymakers, creative leaders, and innovators has come together under the banner of BRIDGE Alliance to advance inclusivity, investment, and sustainable development in the global media, entertainment and content economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112707768/en/ World leaders and industry icons unite under BRIDGE Alliance to empower the future of media, entertainment and content (Photo: AETOSWire) Headquartered in the UAE, BRIDGE Alliance stands as a first-of-its-kind global body chaired by H.E. Abdulla bin Mohammed bin Butti Al Hamed. It brings together an influential board comprising former heads of state, global leaders, policymakers, and CEOs from the media, communication, technology, finance, and creative sectors. The founding board includes HRH Princess Lamia bint Majed Al Saud, CEO of Rotana Media Group and Secretary-General of Alwaleed Philanthropies; H.E. Macky S
Sutherland and Celona Launch AI-Enabled Private 5G and Autonomous Network Solution for Enterprises and Service Providers Globally12.11.2025 15:00:00 EET | Press release
In a move set to redefine how enterprises and service providers manage mission-critical connectivity, Sutherland, a global leader in business and digital transformation, today announced the launch of an AI-enabled Private 5G and Autonomous Network solution in collaboration with Celona, the Silicon Valley innovator that pioneered the 5G LAN architecture. This end-to-end offering brings together Sutherland’s Agentic Service Management Orchestration (SMO) platform and suite of AI-enabled xApps and rApps with Celona’s next-generation private 5G infrastructure. The result is a self-managing, intent-based network that dramatically reduces human intervention while increasing performance, resilience, and sustainability across enterprise and telecom environments. “Enterprises no longer want to manage networks — they want networks that manage themselves,” said Sriram Panchapakesan, Chief Executive Officer of Communications, Media & Entertainment, Sutherland. “By combining autonomy with intellige
Armis Expands Technology Partner Ecosystem to Help Global Organizations Fortify Cyber Defenses12.11.2025 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced 11 new global technology integration partners. These integrations enhance joint customers’ existing technology stacks, enabling them to streamline security operations and reduce their cyber risk exposure. “The era of fragmented security is over – organizations demand best-in-class solutions that work seamlessly together to solve today's most complex cybersecurity challenges,” said Nadir Izrael, CTO and Co-Founder at Armis. “By partnering with other industry leaders, we are not just integrating tools; we are delivering a unified security ecosystem that reduces complexity and empowers joint customers to optimize their technology investments. This supports businesses in staying ahead of threats and protecting their most critical assets with confidence.” New Armis global technology integration partners include BlastWave, Cato Networks, Checkmarx, CyCognito, Elastic, Onyxia Cyber, Profitap, TeamDynamix, Tines, Sygnia,
Vasion Welcomes Cindy White Cybersecurity Expert and Former Microsoft Marketing Leader as Chief Marketing Officer12.11.2025 15:00:00 EET | Press release
Vasion, a leader in serverless printing and AI-enabled automation, today announced the appointment of Cindy White as Chief Marketing Officer, effective October 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112275154/en/ Vasion CMO Cindy White brings more than 25 years of experience leading high performance marketing teams at global technology companies. As organizations accelerate their transition to the cloud, Vasion is redefining what’s possible in the print and process automation landscape. Vasion enables tens of thousands of global customers to start with intelligent print and move to print intelligence, removing friction, cost, and risk from critical print environments, empowering them to move faster with secure, cloud-native, AI-based solutions. “Cindy’s global expertise and proven ability to scale marketing organizations across both direct and partner-driven go-to-markets will be instrumental as Vasion conti
Stealth Third Rock Ventures Backed Company Selects Parse Biosciences GigaLab to Build Largest TCR Atlas for Common Autoimmune Disease12.11.2025 15:00:00 EET | Press release
Third Rock Ventures and Parse Biosciences today announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs) using Parse Biosciences’ GigaLab platform. The project is led by a stealth Third Rock Ventures portfolio company that is developing precision medicines for autoimmune disease. The first-of-its-kind study will generate the world’s largest TCR dataset focused on T-cell mediated autoimmune disease, offering an essential resource to decode disease-driving immune signatures and reveal novel therapeutic targets. The new company will leverage the insights provided by mapping the genetic diversity of TCRs at this massive scale to speed the development of novel precision medicines for underserved patients with limited options today. “This effort positions us to deliver the most comprehensive TCR Atlas for T-cell mediated disease ever assembled,” said Dr. Hugo Hilton, Principal at Third Rock Ventures, who is guiding discovery and development fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom